Advanced Chemical Industries Limited

1st Quarter ended Report 2020 - 2021 for the three months period ended on 30 September 2020

Advanced Chemical Industries Limited Statement of financial position Unaudited

		Fig	gures in '000' Taka
		As at	As at
	Note	30 September 2020	30 June 2020
Assets			
Property, plant and equipment	2	10,762,625	10,664,953
Right-of-use assets		501,019	499,940
Investments	3	2,978,430	2,950,640
Intangible assets		3,531	3,785
Biological assets		12,471	10,915
Deferred tax assets		273,415	214,067
Non-current assets	211	14,531,492	14,344,301
Inventories	4	5,884,558	4,976,120
Trade receivables	5	3,928,711	3,881,479
Other receivables	-	447,853	374,563
Inter-company receivables	6	20,096,404	19,146,539
Advances, deposits and prepayments	7	788,824	743,851
Cash and cash equivalents	5	731,190	787,826
Current assets		31,877,539	29,910,379
Total assets		46,409,031	44,254,680
Equity			
Share capital		573,730	573,730
Share premium		402,310	402,310
Reserves		3,536,880	3,511,868
Retained earnings		11,454,192	10,933,326
Total equity		15,967,111	15,421,234
Liabilities			
Employee benefits	8	1,123,506	1,081,293
Long term borrowings	9	689,130	571,816
Non-current portion of lease liability		385,631	388,549
Non-current liabilities		2,198,268	2,041,658
Bank overdraft		2,379,571	
Loans and borrowings	10	14,827,886	2,502,963 12,134,376
Current portion of lease liability	10	152,188	141,728
Trade payables		1,762,734	1,497,796
Inter-company payables	11	5,097,613	6,838,689
Other payables	12	3,354,154	3,133,616
Current tax liability	12	669,506	542,619
Current liabilities		28,243,652	26,791,787
Total liabilities		30,441,919	28,833,446
Total equity and liabilities		46,409,031	44,254,680

Ianaging Director Director Chief Financial Officer

Financial Officer Company Secretary

Advanced Chemical Industries Limited Statement of profit or loss Unaudited

Unau	uiteu		
		Figu	res in '000' Taka
		For the 1st Quar	ter ended from
		July 2020	July 2019
		to	to
	Note	September 2020	September 2019
Revenue	13	6,819,531	5,535,084
Cost of sales	14	(3,701,176)	(2,800,009)
Gross profit		3,118,355	2,735,076
Administrative, selling and distribution expenses	15	(2,237,843)	(2,184,345)
Other income		9,194	8,517
Operating profit		889,705	559,248
Net finance costs		(121,208)	(174,373)
Profit before contribution to WPPF		768,498	384,875
Contribution to WPPF		(38,425)	(19,244)
Profit before tax		730,073	365,631
Income tax expense		(209,208)	(106,596)
Profit after tax		520,864	259,035
		V II III	
Earnings per share			
Basic and diluted earnings per share (EPS)		9.08	4.51

Managing Director

Director

Chief Financial Officer

Advanced Chemical Industries Limited Statement of profit or loss and other comprehensive income Unaudited

	•	gures in '000' Taka arter ended from
	July 2020 to September 2020	July 2019 to September 2019
Profit after tax	520,864	259,035
Other comprehensive income:		
Change in fair value of FVOCI financial assets	27,791	45,601
Income tax on FVOCI financial assets	(2,779)	(4,560)
Other comprehensive income, net of tax	25,012	41,041
Total comprehensive income	545,876	300,076

Advanced Chemical Industries Limited Statement of changes in equity Unaudited

Figures in '000' Taka

		July 2020 to Sep	020 to September 2020				
	Share capital	Share premium	Capital reserve	FVOCI reserve	Revaluation surplus	Retained earnings	Total equity
Balance at 1 July 2020	573,730	402,310	1,671	434,656	3,075,541	10,933,326	15,421,234
Total comprehensive income							
Profit after tax	-	-	-	-	-	520,864	520,864
Other comprehensive income-net of tax	-	-	-	25,012	-	-	25,012
Total comprehensive income	-	-	-	25,012	-	520,864	545,876
Transaction with owners of the Company							
Share premium	-	-	-	-	-	-	-
Stock dividend	-	-	-	-	-	-	-
Cash dividend	=	=	=	-	=	-	=
Total transactions with owners of the Company	-	-	-	-	-	-	-
Balance at 30 September 2020	573,730	402,310	1,671	459,667	3,075,541	11,454,192	15,967,111

			For tl	ne period up to 1	to 1st Quarter from July 2019 to September 20			
	Share capital	Share premium	Capital reserve	FVOCI reserve	Revaluation surplus	Retained earnings	Total equity	
Balance at 1 July 2019	498,895	402,310	1,671	555,904	3,075,541	9,788,136	14,322,458	
Total comprehensive income								
Profit after tax	-	-	-	-	-	259,035	259,035	
Other comprehensive income-net of tax	-	-	-	41,041	-	-	41,041	
Total comprehensive income	-	-	-	41,041	=	259,035	300,076	
Transaction with owners of the Company								
Share premium	-	-	-	-	-	-	-	
Stock dividend	-	-	-	-	-	-	-	
Cash dividend	-	-	-	-	-	-	-	
Total transactions with owners of the company	-	-	-	-	-	-	-	
Balance at 30 September 2019	498,895	402,310	1,671	596,946	3,075,541	10,047,171	14,622,535	

Advanced Chemical Industries Limited Statement of cash flows Unaudited

		Figures in '000' Taka
	July 2020	arter ended from July 2019
	to	to
	September 2020	September 2019
Cash flows from operating activities		
Cash receipts from customers and others	6,574,734	5,967,905
Cash paid to suppliers and employees	(6,104,506)	(5,178,729)
Cash generated from operating activities	470,228	789,176
Paid to WPPF	(7,469)	(26,332)
Finance costs paid	(106,597)	(148,053
Income tax paid	(144,449)	(110,121)
•	(258,515)	(284,506
Net cash from / (used in) operating activities*	5 211,713	504,670
Cash flows from investing activities Acquisition of property, plant and equipment	(21 176)	(26.270
Payments for capital work in progress	(31,176) (184,562)	(26,270 (354,353
Sale proceeds from property, plant and equipment	(184,302) 762	1,229
Purchase of biological assets	(2,228)	1,229
Net cash (used) in investing activities	(217,204)	(379,394
	· , , , ,	
Cash flows from financing activities		
Inter-company debts received/(paid)	(2,690,938)	(462,963
Dividend paid	(16,502)	(63
Payment for lease liabilities	(31,139)	(52,930)
Short-term bank loan received/(paid)	2,694,514	577,526
Long-term bank loan received/(paid)	116,310	40,424
Net cash (used)/from financing activities	72,245	101,994
Net increase / (decrease) in cash and cash equivalents	66,756	227,272
Cash and cash equivalents at 1 July	(1,715,137)	(1,640,288
Cash and cash equivalents at 30 September	(1,648,381)	(1,413,015
Closing balance represents		
Cash and cash equivalents	731,190	1,325,213
Bank overdraft	(2,379,571)	(2,738,229)
	(1,648,381)	(1,413,015)

^{*}See Note 16 for reconciliation of net operating cash flow.

Advanced Chemical Industries Limited Consolidated statement of financial position Unaudited

	Unaudited		
			Figures in '000' Taka
		As at	As at
	Note	30 September 2020	30 June 2020
Assets			
Property, plant and equipment	2 (a)	26,738,177	26,682,431
Right-of-use assets	- ()	1,443,285	1,505,563
Equity-accounted investees		1,789,768	1,668,822
Other investments		809,692	777,345
Intangible assets		110,236	115,683
Biological assets		12,471	10,915
Deferred tax assets		528,130	398,907
Non-current assets		31,431,761	31,159,665
Inventories	4.7-1	12 020 705	10.545.450
Trade receivables	4 (a)	13,929,705	12,545,672
Other receivables	5 (a)	12,660,598	12,212,919
Inter-company receivables	6 (a)	799,262	670,119
Advances, deposits and prepayments	6 (a)	9,473	9,525
Cash and cash equivalents	7 (a)	2,135,416	2,082,002
Current assets		2,765,341	2,882,922
Total assets		32,299,794 63,731,555	30,403,158 61,562,823
		03,731,333	01,302,823
Equity Share capital		572 720	572 720
Share premium		573,730	573,730
Reserves		402,310	402,310
Retained earnings		4,738,604	4,711,255
Equity attributable to the owners of the company		2,308,410	2,211,343
Non-controlling interest		8,023,054	7,898,638
Total equity		(665,217) 7,357,838	(608,661 7,289,977
Liabilities		1,557,656	1,209,911
Employee benefits	8 (a)	1,418,896	1,367,018
Long term borrowings	9 (a)	8,704,652	8,271,768
Non-current portion of lease liability		1,121,210	1,180,585
Non-current liabilities		11,244,759	10,819,371
Bank overdraft		4,107,913	4,440,894
Loans and borrowings	10 (a)	29,363,490	27,288,288
Current portion of lease liability	(-)	417,172	402,088
Frade payables		4,554,956	4,897,372
Other payables	12 (a)	6,243,755	6,089,293
Current tax liability	~~ (~)	441,672	335,539
Current liabilities		45,128,958	43,453,475
Total liabilities		56,373,717	54,272,846
Total equity and liabilities		63,731,555	61,562,823
Net asset value (NAV) per share	1.000	139.84	137.67

Managing Director

Director

Chief Financial Officer

Company Secretary

Advanced Chemical Industries Limited Consolidated statement of profit or loss Unaudited

Figures in '000' Taka

		For the 1st Qua	For the 1st Quarter ended from			
		July 2020 to	July 2019 to			
	Note	September 2020	September 2019			
Revenue	13 (a)	18,231,892	15,772,482			
Cost of sales	14 (a)	(12,970,326)	(11,045,356)			
Gross profit		5,261,566	4,727,126			
Administrative, selling and distribution expenses	15 (a)	(4,104,136)	(3,978,746)			
Other income / (loss)		93,228	40,598			
Operating profit		1,250,658	788,978			
Share of profit of equity accounted investees		120,947	92,290			
Net finance costs		(923,312)	(1,044,252)			
Profit/ (loss) before contribution to WPPF		448,293	(162,984)			
Contribution to WPPF		(58,400)	(37,935)			
Profit/ (loss) before tax		389,893	(200,918)			
Income tax expense		(349,579)	(191,370)			
Profit/ (loss) after tax		40,314	(392,289)			
Profit/ (loss) attributable to:						
Equity holders of the company		97,067	(299,077)			
Non-controlling interests		(56,753)	(93,212)			
Profit/ (loss) after tax		40,314	(392,289)			
Earnings per share						
Basic and diluted earnings per share (EPS)		1.69	(5.21)			

Managing Director

Director

Chief Financial Officer

Company Secretary

Advanced Chemical Industries Limited Consolidated statement of profit or loss and other comprehensive income Unaudited

Unaudited	Figures in '000' Ta				
	For the 1st Quar	ter ended from			
	July 2020 to September 2020	July 2019 to September 2019			
Profit/ (loss) after tax	40,314	(392,289)			
Other comprehensive income:					
Foreign operations - foreign currency translation differences	2,206	-			
Change in fair value of FVOCI financial assets	28,157	45,356			
Income tax on other comprehensive income	(2,816)	(4,536)			
Other comprehensive income, net of tax	27,547	40,821			
Total comprehensive income	67,861	(351,468)			
Total comprehensive income attributable to:					
Equity holders of the Company					
Profit/ (loss) after tax	97,067	(299,077)			
Other comprehensive income	27,350	40,913			
	124,417	(258,164)			
Non-controlling interest					
Profit/ (loss) after tax	(56,753)	(93,212)			
Other comprehensive income	197	(92)			
	(56,556)	(93,304)			
Total comprehensive income	67,861	(351,468)			

Advanced Chemical Industries Limited Consolidated Statement of changes in equity Unaudited

Figures in '000' Taka
For the period up to 1st Quarter from July 2020 to September 2020

_	Attributable to owner of the Company								_	
	Share capital	Share premium	Capital reserve	Translation reserve	FVOCI reserve	Revaluation reserve	Retained earnings	Total	Non-controlling Interests	Total equity
Balance at 1 July 2020	573,730	402,310	1,671	(1,397)	433,047	4,277,934	2,211,343	7,898,638	(608,661)	7,289,977
Total comprehensive income										
Profit/ (loss) after tax	-	-	-	-	-	-	97,067	97,067	(56,753)	40,314
Other comprehensive income-net of tax	-		-	2,050	25,299	-	-	27,349	197	27,546
Total comprehensive income	-	-	-	2,050	25,299	-	97,067	124,416	(56,556)	67,860
Transaction with owners of the Company										
Share premium	-	-	-	-	-	-	-	-	-	-
Stock dividend	-	-	-	-	-	-	-	-	-	-
Cash dividend	-	-	-	-	-	-	-	-	-	-
Adjustment for transfer of shares in subsidiary	-	-	-	-	-	-	-	-	-	-
Total transactions with owners of the Company	-	-	-	-	-	-	-	-	-	-
Balance at 30 September 2020	573,730	402,310	1,671	654	458,346	4,277,934	2,308,410	8,023,054	(665,217)	7,357,838

For the period up to 1st Quarter from July 2019 to September 2019

	Attributable to owner of the Company									
	Share capital	Share premium	Capital reserve	Translation reserve	Available for sale reserve	Revaluation surplus	Retained earnings	Total	Non-controlling Interests	Total equity
Balance at 1 July 2019	498,895	402,310	1,671	(848)	554,781	4,277,934	3,845,276	9,580,018	(351,284)	9,228,735
Total comprehensive income										
Profit/ (loss) after tax	-	-	-	-	-	-	(299,077)	(299,077)	(93,212)	(392,289)
Other comprehensive income-net of tax	-	-	-	-	40,913	-	-	40,913	(92)	40,821
Total comprehensive income	-	-	-	-	40,913	-	(299,077)	(258,164)	(93,304)	(351,468)
Transaction with owners of the Company										
Share premium	-	-	-	-	-	-	-	-	-	-
Stock dividend	-	-	-	-	-	-	-	-	-	-
Cash dividend	-	-	-	-	-	-	-	-	-	-
Adjustment for transfer of shares in subsidiary	-	-	-	-	-	-	-	-	-	-
Total transactions with owners of the company	=	-	-	-	=	=	-	-	-	-
Balance at 30 September 2019	498,895	402,310	1,671	(848)	595,693	4,277,934	3,546,199	9,321,855	(444,588)	8,877,267

Advanced Chemical Industries Limited Consolidated statement of cash flows Unaudited

		Figures in '000' Tak			
		For the 1st Qua	rter ended from		
		July 2020	July 2019		
		to	to		
		September 2020	September 2019		
Cash flows from operating activities					
Cash receipts from customers and others		17,666,052	16,476,718		
Cash paid to suppliers and employees		(18,265,930)	(15,729,328)		
Cash generated from operating activities		(599,878)	747,390		
Paid to WPPF		(8,513)	(51,902)		
Finance costs paid		(746,276)	(871,724)		
Income tax paid		(376,263)	(239,360)		
•		(1,131,052)	(1,162,985)		
Net cash from / (used in) operating activities *	16 (a)	(1,730,930)	(415,595)		
Cash flows from investing activities					
Acquisition of property, plant and equipment		(94,221)	(398,894)		
Payments for capital work in progress		(343,754)	(252,337)		
Sale proceeds from property, plant and equipment		762	1,229		
Purchase of biological assets		(2,228)	-		
Investment		(1,875)	-		
Net cash used in investing activities		(441,315)	(650,003)		
Cash flows from financing activities					
Inter-company debts received/(paid)		52	37,767		
Dividend paid		(16,502)	(63)		
Payment for lease liabilities		(109,329)	(140,808)		
Paid as dividend to non-controlling interest		(18)	-		
Short-term bank loan received/(paid)		2,557,640	(312,072)		
Long-term bank loan received/(paid)		(43,868)	1,274,290		
Net cash from financing activities		2,387,975	859,113		
Net increase / (decrease) in cash and cash equivalents		215,725	(206,484)		
Cash and cash equivalents at 1 July		(1,557,972)	(2,298,188)		
Effect of movements in exchange rates on cash held		(326)	-		
Cash and cash equivalents at 30 September		(1,342,573)	(2,504,672)		
Closing balance represents					
Cash and cash equivalents		2,765,341	2,324,466		
Bank overdraft		(4,107,913)	(4,829,138)		
		(1,342,573)	(2,504,672)		
Net operating cash flows per share (NOCFPS)		(30.17)	(7.24)		

^{*}See Note 16(a) for reconciliation of consolidated net operating cash flow.

Advanced Chemical Industries Limited Notes to the financial statements as at and for the 1st Quarter ended on 30 September 2020 Unaudited

1 Selected explanatory notes

These financial statements have been prepared in line with Accounting Policies as adopted in the preparation of financial statements for the year ended from 1 July 2019 to 30 June 2020. This interim financial report includes only those selected explanatory notes as were deemed appropriate for better understanding of unaudited financial statements.

Figures in '000' Taka

_		rigures in ooo raka						
2	Property, plant and equipment	30 September 2020	30 June 2020					
		<u> </u>	Taka					
	Opening balance	12,626,796	11,352,682					
	Additions	215,738	1,284,480					
	Disposals	(224)	(10,365)					
	Accumulated depreciation	(2,079,685)	(1,961,843)					
	Closing balance	10,762,625	10,664,953					
2 (a)	Consolidated property, plant and equipment							
	Opening balance	32,253,303	29,600,056					
	Additions	440,031	2,666,697					
	Disposals	(224)	(11,317)					
	Accumulated depreciation	(5,954,934)	(5,573,006)					
	Closing balance	26,738,177	26,682,431					
3	Investments							
	Investment in subsidiaries	1,751,736	1,751,736					
	Investment in joint ventures	510,000	510,000					
	Investment in associates	377,548	377,548					
	Investment in shares	542,196	514,406					
	Investment in FDR/ other deposits	70,550	70,550					
	Impairment	(273,600)	(273,600)					
		2,978,430	2,950,640					
4	Inventories							
	Raw materials	2,013,642	1,524,251					
	Packing materials	627,662	531,724					
	Work-in-process	197,355	206,515					
	Finished goods	2,782,274	2,555,273					
	Goods in transit	761,476	533,457					
	Stores and spares	75,491	69,402					
	Allowance for inventory	(573,342)	(444,500)					
		5,884,558	4,976,120					

		_	ıres in '000' Taka
		30 September 2020	30 June 2020
		Taka	Taka
4 (a)	Consolidated inventories		
	Raw materials	3,800,022	3,315,790
	Packing materials	699,069	585,905
	Work-in-process	329,817	345,348
	Finished goods	8,124,239	7,649,100
	Goods in transit	1,539,762	1,112,551
	Stores & spares	211,326	205,311
	Allowance for inventory	(774,530)	(668,334)
		13,929,705	12,545,672
5	Trade receivables		
	Debts due over six months	2,892,424	3,042,260
	Debts due below six months	1,678,819	1,423,802
	Provision for doubtful debts	(642,531)	(584,583)
		3,928,711	3,881,479
5 (a)	Consolidated trade receivables		
	Debts due over six months	4,764,194	4,696,631
	Debts due below six months	8,956,489	8,503,579
	Provision for doubtful debts	(1,060,085)	(987,291)
		12,660,598	12,212,919
6	Inter-company receivables		
	ACI Logistics Limited	6,675,007	6,238,282
	ACI HealthCare Limited	4,953,893	4,737,689
	ACI Foods Limited	2,877,305	2,883,554
	Premiaflex Plastics Limited	2,878,208	2,463,634
	ACI Formulations Limited	628,827	865,637
	ACI Biotech Limited	807,656	788,595
	ACI Agrolink Limited	695,524	633,046
	Infolytx Bangladesh Limited	368,351	335,374
	ACI Chemicals Limited	198,494	188,194
	Asian Consumer Care (Pvt.) Limited	7,894	7,894
	ACI Godrej Agrovet (Pvt.) Limited	939	939
	Tetley ACI (Bangladesh) Limited	494	546
	Stochastic Logic Limited	116	116
	Computer Technology Limited	30	30
	Creative Communication Limited	3,666	3,009
		20,096,404	19,146,539

		Fign 30 September 2020 Taka	ures in '000' Taka 30 June 2020 Taka	
6 (a)	Consolidated inter-company receivables			
	Computer Technology Limited	30	30	
	Tetley ACI (Bangladesh) Limited	494	546	
	Asian Consumer Care (Pvt.) Limited	7,894	7,894	
	ACI Godrej Agrovet (Pvt.) Limited	939	939	
	Stochastic Logic Limited	116	116	
		9,473	9,525	
7	Advances, deposits & prepayments			
	Advances to staff, suppliers and others	217,058	257,756	
	VAT current account	315,078	240,320	
	Deposits	236,265	215,925	
	Prepayments	20,423	29,850	
		788,824	743,851	
7 (a)	Consolidated advances, deposits & prepayments			
	Advances to staff, suppliers and others	903,394	1,079,057	
	VAT current account	610,134	371,963	
	Advance for capital expenditure	2,833	9,241	
	Deposits	420,123	388,571	
	Prepayments	198,932	233,170	
		2,135,416	2,082,002	
8	Employee benefits			
	Staff gratuity provision	960,619	932,887	
	Other long term employee benefits	162,887	148,405	
		1,123,506	1,081,293	
8 (a)	Consolidated employee benefits			
	Staff gratuity provision	1,185,378	1,152,626	
	Other long term employee benefits	233,518	214,392	
		1,418,896	1,367,018	

		Figu 30 September 2020 Taka	ures in '000' Taka 30 June 2020 Taka
9	Long term borrowings		
	Long term bank loans	689,130	571,816
		689,130	571,816
9 (a)	Consolidated long term borrowings		
	Long term bank loans	8,704,652	8,271,768
		8,704,652	8,271,768
10	Loans and borrowings - short term		
	Short term loan	14,601,485	11,906,971
	Current portion of long term loan	226,401	227,405
		14,827,886	12,134,376
10 (a)	Consolidated loans and borrowings - short term		
	Short term loan	25,363,677	22,822,007
	Current portion of long term loan	3,999,813	4,466,281
		29,363,490	27,288,288
11	Inter company payables		
	ACI Marine and Riverine Technologies Limited	59,531	12,187
	ACI Motors Limited	3,102,012	4,923,968
	ACI Salt Limited	1,295,217	1,294,346
	ACI Pure Flour Limited	613,183	553,167
	ACI Edible Oils Limited	27,670	55,021
		5,097,613	6,838,689

		Figures in '000'			
		30 September 2020 Taka	30 June 2020 Taka		
12	Other payables				
	Accruals	1,931,737	1,689,212		
	Advance from customers	99,157	140,664		
	Security money received from customers	73,153	75,841		
	Workers' profit participation fund	653,187	608,200		
	Unpaid dividend	144,449	160,951		
	Tax and VAT deducted at source	80,049	113,637		
	Employees welfare fund	300,173	262,054		
	Rights share deposit to be refunded	564	564		
	Family day fund	4,974	4,837		
	Non-management staff provident fund	7,006	6,817		
	Unclaimed refund warrant - Zero Coupon Bonds	3,647	3,647		
	Payable for redemption of Zero Coupon Bonds	20,403	20,403		
	Management staff provident fund	9,349	20,894		
	Advertisement and promotional funds	17,736	17,736		
	Development funds	8,570	8,159		
	•	3,354,154	3,133,616		
12 (a)	Consolidated other payables				
	Accruals	4,015,921	3,819,443		
	Advance from customers	422,606	565,444		
	Security money received from customers	124,621	127,570		
	Workers' profit participation fund	863,929	796,687		
	Unpaid dividend	157,012	173,531		
	Provident fund	9,349	20,894		
	Tax and VAT deducted at source	231,577	233,834		
	Employees welfare fund	341,981	282,585		
	Rights share deposit to be refunded	564	564		
	Family day fund	4,974	4,837		
	Non-management staff provident fund	7,006	6,817		
	Unclaimed refund warrant - Zero Coupon Bonds	3,647	3,647		
	Payable for redemption of Zero Coupon Bonds	20,403	20,403		
	Creditors for capital expenditure	13,858	7,141		
	Advertisement and promotional funds	17,736	17,736		
	Development funds	8,570	8,159		
		6,243,755	6,089,293		

Figures in '000' Taka
For the 1st Quarter ended from

	For the 1st Quarter ended from				
	July 2020	July 2019			
	to	to			
		September 2019			
	_	Taka			
Revenue					
Pharmaceuticals	3,146,440	2,995,895			
Animal Health	1,021,815	849,662			
Consumer brands	2,092,321	1,239,144			
Seeds	250,676	268,910			
Fertilizer	276,220	181,473			
		-			
	6,819,531	5,535,084			
Consolidated revenue					
Cross soles	19 690 527	16,088,786			
Inter-company sales		(316,304)			
	18,231,892	15,772,482			
Cost of sales					
Opening stock	4,817,762	5,508,860			
		2,536,246			
		8,045,106			
Closing stock		(5,667,712)			
		2,377,395			
Manufacturing expenses		422,614			
Manufacturing expenses	3,701,176	2,800,009			
Consolidated cost of sales					
On the state of	11.670.764	12 227 772			
		12,237,772			
Purchase		10,387,242			
		22,625,014			
Closing stock		(12,417,016)			
		10,207,999			
Manufacturing expenses		837,357			
	12,970,326	11,045,356			
Administrative, selling and distribution expenses					
Administrative expenses	151 821	49,402			
		216,271			
		1,918,672			
bening expenses					
	2,237,843	2,184,345			
	Pharmaceuticals Animal Health Consumer brands Seeds Fertilizer Animal Genetics and others Consolidated revenue Gross sales Inter-company sales Cost of sales Opening stock Purchase Closing stock Manufacturing expenses Consolidated cost of sales Opening stock Purchase Closing stock Purchase Closing stock Purchase				

Figures in '000' Taka For the 1st Ouarter ended from

		For the 1st Quarter ended from				
		July 2020 July 2019 to to				
		to	to			
		September 2020 Taka	September 2019 Taka			
15 (a)	Consolidated operating expenses					
	Administrative expenses	753,999	559,386			
	Distribution expenses	482,714	426,858			
_	Selling expenses	2,867,423	2,992,502			
-		4,104,136	3,978,746			
16	Reconciliation of net operating cash flow					
	Profit after tax	520,864	259,035			
	Adjustment for non-cash items and others:					
	- Depreciation and amoritisation	118,218	117,274			
	- Provisions	186,790	180,854			
	- Finance cost	14,611	26,320			
	- Tax Expense	64,760	(3,525)			
	- Contribution to WPPF	30,956	(7,088)			
	-Lease and other adjustments	30,375	55,947			
	Changes in:	(4.025.200)	(4.52.004)			
	- Inventories	(1,037,280)	(463,091)			
	- Trade and other receivables	(178,470)	365,557			
	- Advances, deposits and prepayments	(39,282)	148,440			
	- Trade and other payables, employment benefits Net cash from operating activities	500,172 211,713	(175,053) 504,670			
6 (a)	Reconciliation of Consolidated net operating cash flow	7	,			
10 (a)	Profit after tax	40,314	(392,289)			
		10,511	(3)2,20))			
	Adjustment for non-cash items and others:	207 275	2/1 000			
	Depreciation and amoritisationProvisions	387,375 178,989	341,088			
	- Share of profit of equity accounted investees	(120,947)	196,685 (92,290)			
	- Finance cost	177,035	172,528			
	- Tax Expense	(26,684)	(47,990)			
	- Contribution to WPPF	49,887	(13,967)			
	-Lease and other adjustments	109,329	146,038			
	Changes in:					
	- Inventories	(1,490,229)	(997,213)			
	- Trade and other receivables	(649,616)	627,578			
	- Advances, deposits and prepayments	(53,414)	52,860			
	- Trade and other payables, Employment benefits	(332,971)	(408,624)			
	Net cash from operating activities	(1,730,930)	(415,595)			

17 Consolidated operating segments Please see Annexure A.

	For the 1st Quar	ter ended from
	July 2020 to	July 2019 to
	September 2020	September 2019
18 Consolidated EPS, NAV per share, and NOCFPS		
Weighted average number of ordinary shares (in thousand)	57,373	57,373
Consolidated profit attributable to equity		
holders of the Company (Taka '000)	97,067	(299,077)
Earnings per share (Taka)	1.69	(5.21)
Consolidated cash flows from operating activities		
(Taka '000)	(1,730,930)	(415,595)
Net operating cash flows per share (NOCFPS)	(30.17)	(7.24)
	30 September 2020	30 June 2020
	Taka	Taka
Consolidated net asset attributable to equity holders		
of the Company (Taka '000)	8,023,054	7,898,638
Net asset value (NAV) per share	139.84	137.67

The Group has achieved a decent revenue growth during the period. The growth in revenue and gross profit in the consolidated results during the 1st quarter of FY 2020-21 exceeded the growth in operating expenses. As a result, EPS has demonstrated a positive move compared to the SPLY. The consequential results of positive consolidated profit ultimately contributed to consolidated EPS and NAV per share. On the other hand, NOCFPS reduced due to investing on working capital to facilitate sales growth.

Figures have been rounded off to the nearest '000' Taka and previous period's figures have been rearranged to conform to current period's presentation.

Annexure-A
Consolidated operating segments

Figures in '000' Taka For the period up to 1st Quarter from July 2020 to September 2020

					Reportal	ole Segment						Total	Unallocated/	
Particulars	Pharmaceuticals	Animal Health	Consumer Brands	Crop Care and Public Health	Motors	Pure Flour	Retail Chain	Salt	Foods	Premiaflex	HealthCare	reportable segments	Elimination	Total
External revenue	2 146 440	1,021,815	2.025.912	636,709	2.564.374	1.209.909	2,968,541	368,235	1.513.103	1,336,581	449,693	17,241,312	990,580	18,231,892
External revenue Inter-segment revenue	3,146,440	1,021,813	157,330	030,709	1,116	10,874	10,362	11,736	52,200	1,330,381	449,093	378,150	70,485	448,635
Segment revenue	3,146,440	1,021,815	2,183,242	636,709	2,565,490	1,220,783	2,978,902	379,971	1,565,303	1,471,113	449,693	17,619,462	1,061,065	18,680,527
Depreciation and amortisation	76,514	6,281	19,687	5,629	16,232	8,695	47,271	12,780	16,014	63,712	86,608	359,424	27,951	387,375
Operating expenses	1,325,821	215,418	630,333	114,527	379,762	66,353	590,115	65,735	124,536	138,700	295,933	3,947,233	156,902	4,104,136
Finance cost / (income)	32,870	31,040	17,310	34,003	60,339	(9,991)	312,677	(14,193)	73,930	111,474	202,216	851,675	71,637	923,312
Segment profit/(loss) before tax	616,403	71,661	(3,941)	56,461	250,709	16,172	(346,852)	49,216	16,880	25,627	(459,346)	292,988	96,904	389,893
Segment assets at 30 Sep 2020	10,301,234	2,201,098	5,658,251	2,701,431	11,343,594	1,705,645	3,476,167	2,501,438	2,196,626	6,212,874	9,516,234	57,814,591	5,916,964	63,731,555
Segment liabilities at 30 Sep 2020	4,869,419	1,158,493	2,422,910	1,997,613	8,068,727	568,871	15,792,765	1,201,762	3,994,227	5,602,841	11,791,026	57,468,654	(1,094,937)	56,373,717

For the period up to 1st Quarter from July 2019 to September 2019

					Reporta	ble segment						Total	Unallocated/	
Particulars	Pharmaceuticals	Animal Health	Consumer Brands	Crop Care and Public Health	Motors	Pure Flour	Retail Chain	Salt	Foods	Premiaflex	HealthCare	reportable segments	Elimination	Total
External revenue	2,995,895	849,662	1,165,157	539,736	2,708,827	1,146,083	2,665,429	450,107	1,114,283	871,810	534,833	15,041,822	730,660	15,772,482
Inter-segment revenue	-	-	161,291	-	614	6,911	5,688	9,926	7,774	92,295		284,500	31,804	316,304
Segment revenue	2,995,895	849,662	1,326,448	539,736	2,709,441	1,152,995	2,671,117	460,032	1,122,057	964,106	534,833	15,326,322	762,464	16,088,786
Depreciation and amortisation	77,025	7,587	20,451	8,363	13,634	8,204	56,959	13,009	15,657	62,918	34,553	318,360	22,728	341,088
Operating expenses	1,374,665	236,196	609,077	136,494	400,700	68,081	571,002	65,356	132,147	101,722	254,565	3,950,004	28,742	3,978,746
Finance cost / (income)	33,410	60,050	91,670	50,610	105,659	(13,424)	346,346	(8,941)	95,508	121,969	108,738	991,595	52,656	1,044,252
Segment profit/(loss) before tax	532,208	(8,638)	(309,176)	14,037	267,396	29,503	(393,980)	44,335	(36,491)	(135,674)	(382,264)	(378,743)	177,824	(200,918)
Segment assets at 30 June 2020	9,773,635	2,244,885	5,167,266	2,810,476	12,187,543	1,843,553	3,508,328	2,490,900	2,407,971	5,808,493	9,640,107	57,883,156	3,679,667	61,562,823
Segment liabilities at 30 June 2020	4,692,047	819,562	1,473,492	1,966,169	9,083,288	711,620	15,460,132	1,223,639	4,203,136	5,206,289	11,496,979	56,336,353	(2,063,507)	54,272,846